Clinical trials: Infusions, Intravenous
Acute, Post-operative Pain
Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ST-2427
This randomized, double-blind, placebo controlled, study will be conducted to evaluate the safety, tolerability, and pharmacokinetics of ST-2427.
- Trial name
- NCT04475198
- Testing
- ST-2427
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- SiteOne Therapeutics, Inc.
Neoplasms
Dose Finding Study of BI 836880 in Patients With Solid Tumors
This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours.
- Trial name
- NCT02674152
- Testing
- BI 836880
- Where
- 3 sites in France, Germany
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Advanced or Recurrent Colorectal Cancer
Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
The efficacy and safety of panitumumab (Vectibix) in the routine clinical setting will be studied. Specifically, information will be collected on the following as events of interest: skin disorders, interstitial lung disease…
- Trial name
- NCT02089737
- Testing
- Panitumumab
- Volunteers
- 3,091 people
- Sponsor
- Takeda
Rheumatoid Arthritis
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis
This randomized, double-blind, parallel group study compares the efficacy and safety of subcutaneous (sc) versus intravenous (iv) administration of tocilizumab in participants with moderate to severe active rheumatoid arthritis.
- Trial name
- NCT01194414
- Testing
- tocilizumab SC, tocilizumab IV, Disease-modifying antirheumatic drugs (DMARDs)
- Where
- 216 sites in United States, Argentina and 24 more
- Volunteers
- 1,262 people
- Sponsor
- Hoffmann-La Roche
Pain
Efficacy of IV Lidocaine at Alleviating Pain Associated With Propofol Infusion in Pediatric Patients Undergoing Sedation
This protocol describes a double-blind, placebo-controlled trial intended to demonstrate the effectiveness of lidocaine at reducing pain associated wiht propofol infusion for short-term deep sedation in children.
- Trial name
- NCT00786916
- Testing
- normal saline, lidocaine
- Where
- United States
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Akron Children's Hospital
Healthy
Pharmacokinetics (PK) of Ertapenem Intravenous (IV) Bolus Versus Standard Infusion
The purpose of this study is to characterize and compare the concentration-time profiles and multiple dose pharmacokinetics of a 5 minute intravenous (IV) bolus of ertapenem 1 gram daily versus the standard 30 minute infusion in…
- Trial name
- NCT01148771
- Testing
- ertapenem
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hartford Hospital
Intravenous Administration
Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement
The purpose of this study is to compare the anxiety and pain levels of patients when using Buzzy with ice, Vapocoolant, and placebo when inserting IV's line for IV fluids and/or phlebotomy in pediatric patients in the pediatric…
- Trial name
- NCT06182631
- Testing
- Buzzy Bee, Vapocoolent
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Subarachnoid Hemorrhage
Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage
The hypothesis is that intravenous infusion of sodium nitrite is safe and effective for the reversal of cerebral vasospasm after subarachnoid hemorrhage in patients with a cerebral aneurysm.
- Trial name
- NCT02176837
- Testing
- Sodium Nitrite
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Hope Pharmaceuticals
Cardiac Failure, Myocardial Failure
An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
The purpose of this study is to investigate continuous 8-hour introductions of BMS-986231 in participants with heart failure and weakened heart function given a standard dose of diuretic.
- Conditions
- Cardiac Failure, Myocardial Failure, Congestive Heart Failure, Heart Decompensation
- Trial name
- NCT03730961
- Testing
- BMS-986231, Furosemide
- Where
- 2 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Bristol-Myers Squibb
Viral Disease
First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.
It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety, tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2 virus infection.
- Trial name
- NCT04535167
- Testing
- PF-07304814
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 26 people
- Sponsor
- Pfizer
Lupus Nephritis
Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg
The purpose of this study is to determine whether abatacept at a dose 30 mg/kg via intravenous infusion is safe and well tolerated in the treatment of lupus nephritis in mainland Chinese subjects with systemic lupus erythematosus…
- Trial name
- NCT00705367
- Testing
- Abatacept
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Asthma
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
To evaluate the effect of MEDI-528 in adults with atopic asthma.
- Trial name
- NCT00483041
- Testing
- MEDI528 9 mg/kg
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Covid19
Intravenous Infusion of CAP-1002 in Patients With COVID-19
This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition…
- Trial name
- INSPIRE (NCT04623671)
- Testing
- CAP-1002
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- Capricor Inc.
Hyperglycemia
Comparative Trial Between 3 Types of Insulin Infusion Protocols
Increasing evidence from observational studies in hospitalized patients with and without diabetes indicates that hyperglycemia is a predictor of poor outcome.
- Trial name
- NCT00582309
- Testing
- Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
- Where
- 3 sites in United States
- Volunteers
- 151 people
- Sponsor
- University of New Mexico
Monitoring, Intraoperative
Effects of IV Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris
This study evaluates effects of the analgesic ketamine on ANI measurements (Anti Nociceptive Index)
- Trial name
- NCT01717521
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Washington
Asthma
Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma
This study is a preliminary proof of efficacy study of AIN457 in patients with bronchial asthma that is poorly controlled with the current standard of care.
- Trial name
- NCT01478360
- Testing
- AIN457 (secukinumab)
- Where
- 9 sites in Germany, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Alpha1-antitrypsin Deficiency, Healthy Volunteers
GLASSIA Infusion Rate Study
The purpose of this study was to generate sufficient safety and tolerability information in support of an increase in the infusion rate of intravenous GLASSIA in the prescribing information from 0.04 to 0.2 mL/kg/min.
- Trial name
- NCT01651351
- Testing
- Alpha1-proteinase inhibitor
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baxalta now part of Shire
Major Depressive Disorder With Suicidal Ideation With Intent
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent
Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder (MDD) in subjects who have suicidal ideation with intent
- Trial name
- NCT04722666
- Testing
- MIJ821 Intravenous Injection
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Hepatocellular Carinoma
A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer
This study is to determine how effectively JX-594 (Pexa-Vec) will prolong life in patients with advanced Hepatocellular Carcinoma (HCC) who have not been previously treated with sorafenib, and the safe administration of JX-594 in…
- Trial name
- FLASH (NCT01636284)
- Testing
- JX-594 recombinant vaccina GM-CSF
- Where
- 5 sites in United States, South Korea and 1 more
- Volunteers
- 16 people
- Sponsor
- Jennerex Biotherapeutics
Leukaemia
First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome
Primary Objective: Dose escalation: To determine the maximum tolerated dose (MTD) of SAR440234 administered as a single agent in participants with relapsed or refractory acute myeloid leukemia (R/R AML), high risk myelodysplastic…
- Trial name
- NCT03594955
- Testing
- SAR440234
- Where
- 4 sites in United States, France
- Volunteers
- 7 people
- Sponsor
- Sanofi